Skip to main content
    A

    Arcturus Therapeutics Holdings Inc (ARCT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.27
    +0.15 (+1.35%)

    Market Cap: $323.79M

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    59%(23/39)
    Avg Surprise
    +2.98%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.68
    Range$-0.92 - $-0.29
    10 analysts
    EPS Revisions
    8
    0
    7d
    8
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.88+22.5%
    60d ago$-0.67-0.9%
    30d ago$-0.67-1.5%
    7d ago$-0.67-1.5%
    Current$-0.68
    Revenue Consensus
    $8M
    Range$2M - $16M
    13 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.73
    Range$-1.86 - $-0.23
    10 analysts
    Revenue Consensus
    $607860
    Range$-9701830 - $15M
    13 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.73---
    Sep 26EST
    		-$-0.68---
    Jun 26
    Reported Aug 6
    		$-0.84$-1.07+21.50%Beat-147.1%
    Mar 26
    Reported May 7
    		$-0.95$-1.01+6.25%Beat-82.7%
    Dec 25
    Reported Mar 3
    		$-1.03$-0.76-35.53%Miss+7.2%
    Sep 25
    Reported Nov 10
    		$-0.49$-0.80+38.75%Beat-88.5%
    Jun 25
    Reported Aug 11
    		$-0.34N/A+60.00%Beat+46.9%
    Mar 25
    Reported May 12
    		$-0.52N/A+52.73%Beat+48.0%
    Dec 24
    Reported Mar 6
    		$-1.11$-0.49-124.56%Miss-246.9%
    Sep 24
    Reported Nov 7
    		$-0.26N/A+74.51%Beat+57.4%
    Jun 24
    Reported Aug 5
    		$-0.64N/A+59.24%Beat+67.7%
    Mar 24
    Reported May 8
    		$-1.00$-1.14+12.28%Beat-258.7%
    Dec 23
    Reported Mar 7
    		$-0.32N/A+67.68%Beat-107.2%
    Sep 23
    Reported Nov 14
    		$-0.61N/A+62.58%Beat+54.1%
    Jun 23
    Reported Aug 7
    		$-1.98$-0.42-371.43%Miss-141.5%
    Mar 23
    Reported May 9
    		$0.63$0.26+142.31%Beat+132.5%
    Dec 22
    Reported Mar 28
    		$4.43$0.98+352.04%Beat+401.4%
    Sep 22
    Reported Nov 9
    		$-1.33$-1.81+26.52%Beat+35.1%
    Jun 22
    Reported Aug 9
    		$-0.82N/A+56.38%Beat+60.4%
    Mar 22
    Reported May 9
    		$-1.94$-1.40-38.57%Miss+9.8%
    Dec 21
    Reported Feb 28
    		$-1.47$-1.72+14.53%Beat-17.6%
    Sep 21
    Reported Nov 8
    		$-2.05$-1.52-34.87%Miss-122.8%
    Jun 21
    Reported Aug 9
    		$-2.07$-2.25+8.00%Beat-276.4%
    Mar 21
    Reported May 10
    		$-2.15$-1.23-74.80%Miss-220.9%
    Dec 20
    Reported Mar 1
    		$-1.25$-0.88-42.05%Miss-64.5%
    Sep 20
    Reported Nov 9
    		$-0.92$-0.49-87.76%Miss-64.3%
    Jun 20
    Reported Aug 10
    		$-0.55$-0.55+0.00%Beat-685.7%
    Mar 20
    Reported May 7
    		$-0.67$-0.61-9.84%Miss+1.5%
    Dec 19
    Reported Mar 11
    		$-0.76$-0.51-49.02%Miss-850.0%
    Sep 19
    Reported Nov 7
    		$-0.56$-0.46-21.74%Miss-33.3%
    Jun 19
    Reported Aug 15
    		$-0.07N/A+88.52%Beat+92.9%
    Mar 19
    Reported May 13
    		$-0.68$-0.60-13.33%Miss+37.0%
    Dec 18
    Reported Mar 18
    		$-0.08N/A+83.33%Beat+92.6%
    Sep 18
    Reported Oct 1
    		$-0.42$-0.35-20.00%Miss+40.0%
    Jun 18
    Reported Sep 28
    		$-0.99$-0.70-41.43%Miss-8.8%
    Mar 18
    Reported Apr 2
    		$-1.08$-0.46-134.78%Miss-18.7%
    Dec 17
    Reported Feb 15
    		$-1.08$-0.46-134.78%Miss+29.9%
    Sep 17
    Reported Nov 9
    		$-0.70N/A+73.68%Beat-
    Jun 17
    Reported Aug 11
    		$-0.91$-0.94+3.19%Beat-
    Mar 17
    Reported May 30
    		$-0.91$-1.26+27.78%Beat-
    Dec 16
    Reported Feb 15
    		$-1.54$-1.90+18.95%Beat-

    Key Metrics

    Valuation
    P/E Ratio-3.40EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-863.00%
    ROE-46.30%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio5.88xQuick Ratio5.88x
    Trading Statistics
    Beta2.48Avg Volume791.71K
    52-Week High$24.1752-Week Low$5.50

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$12.71
    SMA 20$13.43
    SMA 50$13.00
    SMA 200$8.78
    EMA 10$12.49
    EMA 20$13.08
    EMA 50$12.49
    EMA 200$10.21

    MACD

    Line: -0.47Signal: -0.09Hist: -0.38

    ADX

    ADX: 19.0+DI: 20.9-DI: 27.1

    Aroon & PSAR

    Aroon Up20.0
    Aroon Down100.0
    PSAR$13.79

    Bollinger Bands

    Upper Band$15.79
    Lower Band$11.06
    %B Position3519%(Upper)
    Band Width0.04

    RSI (14-Day)

    Neutral
    39.4

    Momentum Oscillators

    Stoch %K6.9
    Stoch %D13.8
    Williams %R-85.9
    ROC (10d)-14.7%
    Momentum-1.94
    CCI (20d)-189.1
    MFI (14d)32.8

    Volatility Measures

    ATR (14d)$1.20(10.7%)
    StdDev (20d)1.18
    Hist Vol94.7%(High)

    Volume Flow

    VWAP$11.11
    OBV4.8M
    AD Line1.3M
    CMF (20d)-0.253

    Volume Metrics

    Avg Vol (20d)763.2K
    Vol Ratio0.6x
    VWMA (20d)$13.67

    Pivot Points

    R3$12.75
    R2$12.40
    R1$11.76
    Pivot Point$11.41
    S1$10.77
    S2$10.42
    S3$9.78

    Advanced Oscillators

    TSI-9.52
    Ultimate Osc40.9
    KST-44.35

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$2.96M$2.06M$7.20M$17.15M$28.30M$29.38M$22.77M$41.67M$49.86M$38.01M$30.86M$45.14M
    Cost of Revenue$0$0$682,000$0$0$0$819,000$0$0$0$815,000$0
    Gross Profit$2.96M$2.06M$7.20M$17.15M$28.30M$29.38M$22.77M$41.67M$49.86M$38.01M$30.86M$45.14M
    Operating Expenses$28.50M$30.99M$38.50M$33.66M$39.92M$46.21M$56.16M$52.41M$70.98M$68.42M$49.13M$64.45M
    R&D$17.52M$21.53M$24.48M$23.27M$29.58M$34.89M$43.78M$39.13M$58.67M$53.57M$36.62M$51.08M
    SG&A$10.99M$9.46M$14.03M$10.40M$10.34M$11.31M$12.38M$13.28M$12.32M$14.85M$12.51M$13.38M
    Operating Income$-25,545,000$-28,931,000$-31,306,000$-16,512,000$-11,616,000$-16,826,000$-33,394,000$-10,737,000$-21,126,000$-30,412,000$-18,272,000$-19,314,000
    Interest Income$1.82M$1.93M$0$0$2.57M$2.77M$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-23,785,000$-26,964,000$-29,083,000$-13,448,000$-9,176,000$-14,076,000$-30,010,000$-7,120,000$-17,366,000$-26,449,000$-11,445,000$-15,329,000
    Income Tax Expense$0$0$-4,000$0$4,000$0$-5,000$-217,000$-150,000$368,000$262,000$893,000
    Net Income$-23,785,000$-26,964,000$-29,079,000$-13,448,000$-9,180,000$-14,076,000$-30,005,000$-6,903,000$-17,216,000$-26,817,000$-11,707,000$-16,222,000
    EBITDA$-24,961,000$-28,238,000$-28,401,000$-12,685,000$-10,964,000$-16,046,000$-29,191,000$-6,208,000$-16,457,000$-25,545,000$-10,630,000$-14,502,000
    EBIT$-25,604,000$-28,896,000$-29,083,000$-13,448,000$-11,743,000$-16,847,000$-30,010,000$-7,120,000$-17,366,000$-26,449,000$-11,445,000$-15,329,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ARCT

    News

    Transcript: Arcturus Therapeutics Q2 2026 Earnings Conference Call

    Arcturus Therapeutics reported its Q2 2026 earnings, highlighting continued progress in its rare disease pipeline, including ARCT032 for cystic fibrosis and ARCT810 for OTC deficiency...

    Benzinga•10/14/26•Bullish

    FEDERATED HERMES, INC. Trims Arcturus Therapeutics Holdings Inc (ARCT) Stake -- Shares Look 467% Overvalued on GF Value

    FEDERATED HERMES, INC. has significantly reduced its stake in Arcturus Therapeutics Holdings Inc (ARCT) by 49.21%, selling 1,625,571 shares at $13.69 each. This move leaves the investment firm with 1,678,069 shares...

    GuruFocus•10/13/26•Bearish

    A trust joins the reporting parties for 1.68M Arcturus Therapeutics (ARCT) shares.

    Federated Hermes, Inc. and Voting Shares Irrevocable Trust have filed an amended ownership report for Arcturus Therapeutics Holdings Inc. (ARCT), disclosing beneficial ownership of 1,678,069 shares...

    Stock Titan•10/7/26•Neutral

    Discipline and Rules-Based Execution in ARCT Response

    Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is exhibiting neutral near-term sentiment that could lead to mid-term weakness...

    Stock Traders Daily•10/6/26•Neutral

    Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform

    Arcturus Therapeutics announced encouraging preliminary Phase II data for its ARCT-810 program for OTC deficiency...

    Yahoo Finance•9/24/26•Bullish

    ARCT Valuation and Fair Value

    P/E
    -3.4x
    Forward P/E
    2.5x
    P/B
    1.9x
    See GNG's fair value

    ARCT Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -863.0%
    Net margin
    0.0%
    ROE
    -46.3%
    FCF margin
    -248.6%

    ARCT Competitors

    CompanyTicker
    Enanta Pharmaceuticals IncENTA
    Sanara Medtech IncSMTI
    Semler Scientific IncSMLR
    Canopy Growth CorpCGC
    Orchestra BioMed Holdings Inc.OBIO
    Indaptus Therapeutics IncINDP
    Opus Genetics, Inc.IRD
    Contineum Therapeutics, Inc. Class A Common StockCTNM

    Sector: Healthcare

    ARCT Analyst Ratings

    Consensus
    Buy
    Analysts
    13
    Strong Buy
    1
    Buy
    10
    Hold
    2
    Sell
    0
    Strong Sell
    0

    ARCT Bull Case vs Bear Case

    Bull case

    • ARCT beat EPS estimates in 75.0% of its last 8 reported quarters.
    • 84.6% of ARCT's analyst ratings are Buy or Strong Buy.

    Bear case

    • ARCT's quarterly revenue changed -89.5% year over year.

    ARCT Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    11.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.68
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    8 up, 1 down

    Frequently Asked Questions About ARCT

    Does ARCT pay dividends?

    Arcturus Therapeutics Holdings Inc (ARCT) does not currently pay a regular dividend.

    What is ARCT's market cap?

    Arcturus Therapeutics Holdings Inc (ARCT) has a market capitalization of $323.79M with a current stock price of $11.27.

    Related stocks

    Sector: Healthcare

    All stocks starting with A

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In